MicroRNA-122-5p Aggravates Angiotensin II-Mediated Myocardial Fibrosis and Dysfunction in Hypertensive Rats by Regulating the Elabela/Apelin-APJ and ACE2-GDF15-Porimin Signaling.

Angiotensin II / adverse effects Angiotensin-Converting Enzyme 2 / metabolism Animals Apelin / metabolism Cardiomyopathies Fibrosis Growth Differentiation Factor 15 / metabolism Hypertension / chemically induced Inflammation MicroRNAs / genetics Rats
Elabela Hypertension Myocardial fibrosis Oncosis miR-122-5p

Journal

Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585

Informations de publication

Date de publication:
06 2022
Historique:
received: 06 12 2021
accepted: 31 01 2022
pubmed: 18 2 2022
medline: 24 6 2022
entrez: 17 2 2022
Statut: ppublish

Résumé

Hypertension is the leading risk factor for cardiovascular disorders. This study aimed to explore roles of microRNA (miR)-122-5p in hypertension. Angiotensin II (Ang II; 1.5 mg/kg/day) with an osmotic minipump was used to induce hypertensive rats pretreated by rAAV-miR-122-5p or rAAV-GFP, respectively. Notably, Ang II infusion caused marked increases in myocardial fibrosis, inflammation, oncosis, and oxidant injury in rats, which were aggravated by rAAV-miR-122-5p. RAAV-miR-122-5p exacerbated Ang II-mediated cardiac dysfunction and structural injury in hypertensive rats, with downregulated levels of apelin, elabela, ACE2, and GDF15, as well as upregulated expression of porimin and CTGF. In cultured rat cardiac fibroblasts, Ang II contributed to augmentation of cellular oncosis, migration, inflammation, and oxidative stress, with reduction of apelin, elabela, ACE2, and GDF15 levels, which were rescued by miR-122 inhibitor. In summary, miR-122-5p exacerbates myocardial fibrosis and dysfunction in hypertensive rats by modulating the elabela/apelin-ACE2-GDF15 signaling. MiR-122-5p has potential therapeutic significance for hypertension and hypertensive cardiac injury.

Identifiants

DOI: 10.1007/s12265-022-10214-3 PMID: 35174434 PMC: PMC8853151
pubmed: 35174434
doi: 10.1007/s12265-022-10214-3
pii: 10.1007/s12265-022-10214-3
pmc: PMC8853151
doi:

Substances chimiques

Apelin 0
Gdf15 protein, rat 0
Growth Differentiation Factor 15 0
MIRN122 microRNA, rat 0
MicroRNAs 0
Angiotensin II 11128-99-7
Ace2 protein, rat EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

535-547

Subventions

Organisme : National Natural Science Foundation of China
ID : 81770253
Organisme : National Natural Science Foundation of China
ID : 91849111
Organisme : National Natural Science Foundation of China
ID : 81370362
Organisme : National Natural Science Foundation of China
ID : 92168117

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., Wang, J., Zhu, M., Weintraub, W. S., Gao, R., & China Hypertension Survey, I. (2018). Status of hypertension in China: Results from the China Hypertension Survey, 2012–2015. Circulation., 137, 2344–2356. https://doi.org/10.1161/CIRCULATIONAHA.117.032380
doi: 10.1161/CIRCULATIONAHA.117.032380 pubmed: 29449338
Gonzalez, A., Ravassa, S., Lopez, B., Moreno, M. U., Beaumont, J., San, Jose G., Querejeta, R., Bayes-Genis, A., & Diez, J. (2018). Myocardial remodeling in hypertension. Hypertension., 72, 549–558. https://doi.org/10.1161/HYPERTENSIONAHA.118.11125
doi: 10.1161/HYPERTENSIONAHA.118.11125 pubmed: 30354762
Arkoumani, M., Papadopoulou-Marketou, N., Nicolaides, N. C., Kanaka-Gantenbein, C., Tentolouris, N., & Papassotiriou, I. (2020). The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Crit. Rev. Clin. Lab. Sci., 57, 114–125. https://doi.org/10.1080/10408363.2019.1678565
doi: 10.1080/10408363.2019.1678565 pubmed: 31663791
Adela, R., Mohammed, S. A., Kanwal, A., Vishwakarma, G., Chander Reddy, P. N., & Banerjee, S. K. (2016). Elevated levels of GDF-15 is associated with increased angiotensin II in hypertensive patients with type 2 diabetes. Per. Med., 13, 325–336. https://doi.org/10.2217/pme-2016-0030
doi: 10.2217/pme-2016-0030 pubmed: 29749818
Wang, J., Liu, S., Heallen, T., & Martin, J. F. (2018). The Hippo pathway in the heart: Pivotal roles in development, disease, and regeneration. Nat. Rev. Cardiol., 15, 672–684. https://doi.org/10.1038/s41569-018-0063-3
doi: 10.1038/s41569-018-0063-3 pubmed: 30111784
Niu, L., Jia, Y., Wu, M., Liu, H., Feng, Y., Hu, Y., Zhang, X., Gao, D., Xu, F., & Huang, G. (2020). Matrix stiffness controls cardiac fibroblast activation through regulating YAP via AT1 R. J. Cell. Physiol., 235, 8345–8357. https://doi.org/10.1002/jcp.29678
doi: 10.1002/jcp.29678 pubmed: 32239716
Francisco, J., Zhang, Y., Jeong, J. I., Mizushima, W., Ikeda, S., Ivessa, A., Oka, S., Zhai, P., Tallquist, M. D., & Del Re, D. P. (2020). Blockade of fibroblast YAP attenuates cardiac fibrosis and dysfunction through MRTF-A inhibition. JACC Basic Transl Sci., 5, 931–945. https://doi.org/10.1016/j.jacbts.2020.07.009
doi: 10.1016/j.jacbts.2020.07.009 pubmed: 33015415 pmcid: 7524792
Liu, Y., Song, J. W., Lin, J. Y., Miao, R., & Zhong, J. C. (2020). Roles of microrna-122 in cardiovascular fibrosis and related diseases. Cardiovasc. Toxicol., 20, 463–473. https://doi.org/10.1007/s12012-020-09603-4
doi: 10.1007/s12012-020-09603-4 pubmed: 32856216 pmcid: 7451782
Weber, G. J., Purkayastha, B., Ren, L., Pushpakumar, S., & Sen, U. (2018). Hypertension exaggerates renovascular resistance via miR-122-associated stress response in aging. J. Hypertens., 36, 2226–2236. https://doi.org/10.1097/HJH.0000000000001770
doi: 10.1097/HJH.0000000000001770 pubmed: 30256768
Song, J. J., Yang, M., Liu, Y., Song, J. W., Wang, J., Chi, H. J., Liu, X. Y., Zuo, K., Yang, X. C., & Zhong, J. C. (2020). MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur. J. Pharmacol., 883, 173374. https://doi.org/10.1016/j.ejphar.2020.173374
doi: 10.1016/j.ejphar.2020.173374 pubmed: 32682786 pmcid: 7364171
Sato, T., Suzuki, T., Watanabe, H., Kadowaki, A., Fukamizu, A., Liu, P. P., Kimura, A., Ito, H., Penninger, J. M., Imai, Y., & Kuba, K. (2013). Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest., 123, 5203–11. https://doi.org/10.1172/JCI69608
doi: 10.1172/JCI69608 pubmed: 24177423 pmcid: 3859384
Xu, R., Zhang, Z. Z., Chen, L. J., Yu, H. M., Guo, S. J., Xu, Y. L., Oudit, G. Y., Zhang, Y., Chang, Q., Song, B., Chen, D. R., Zhu, D. L., & Zhong, J. C. (2016). Ascending aortic adventitial remodeling and fibrosis are ameliorated with Apelin-13 in rats after TAC via suppression of the miRNA-122 and LGR4-beta-catenin signaling. Peptides., 86, 85–94. https://doi.org/10.1016/j.peptides.2016.10.005
doi: 10.1016/j.peptides.2016.10.005 pubmed: 27773659
Song J.W., Tang J.Q., Zhang Z.Z., Liu Y.&Zhong J.C. (2021) Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension. Chin. Med. J. (Engl.). https://doi.org/10.1097/cm9.0000000000001766
Zhang, Z. Z., Wang, W., Jin, H. Y., Chen, X., Cheng, Y. W., Xu, Y. L., Song, B., Penninger, J. M., Oudit, G. Y., & Zhong, J. C. (2017). Apelin Is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction. Hypertension., 70, 1165–1175. https://doi.org/10.1161/HYPERTENSIONAHA.117.10156
doi: 10.1161/HYPERTENSIONAHA.117.10156 pubmed: 28974565
D’Arcy, M. S. (2019). Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol. Int., 43, 582–592. https://doi.org/10.1002/cbin.11137
doi: 10.1002/cbin.11137 pubmed: 30958602
Hein, S., Arnon, E., Kostin, S., Schonburg, M., Elsasser, A., Polyakova, V., Bauer, E. P., Klovekorn, W. P., & Schaper, J. (2003). Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation., 107, 984–91. https://doi.org/10.1161/01.cir.0000051865.66123.b7
doi: 10.1161/01.cir.0000051865.66123.b7 pubmed: 12600911
Ricci, M. S., & Zong, W. X. (2006). Chemotherapeutic approaches for targeting cell death pathways. Oncologist., 11, 342–57. https://doi.org/10.1634/theoncologist.11-4-342
doi: 10.1634/theoncologist.11-4-342 pubmed: 16614230
Du, J. H., Zhang, H. D., Ma, Z. J., & Ji, K. M. (2010). Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother. Pharmacol., 65, 895–902. https://doi.org/10.1007/s00280-009-1095-5
doi: 10.1007/s00280-009-1095-5 pubmed: 19690861
Chu, J., Ji, H., Lu, M., Li, Z., Qiao, X., Sun, B., Zhang, W., & Xue, D. (2013). Proteomic analysis of apoptotic and oncotic pancreatic acinar AR42J cells treated with caerulein. Mol. Cell. Biochem., 382, 1–17. https://doi.org/10.1007/s11010-013-1603-0
doi: 10.1007/s11010-013-1603-0 pubmed: 23884867
Chen, B., Lu, D., Fu, Y., Zhang, J., Huang, X., Cao, S., Xu, D., Bin, J., Kitakaze, M., Huang, Q., & Liao, Y. (2014). Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53. Br. J. Pharmacol., 171, 3741–53. https://doi.org/10.1111/bph.12736
doi: 10.1111/bph.12736 pubmed: 24749959 pmcid: 4128070
Patel, V. B., Zhong, J. C., Grant, M. B., & Oudit, G. Y. (2016). Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure. Circ. Res., 118, 1313–26. https://doi.org/10.1161/CIRCRESAHA.116.307708
doi: 10.1161/CIRCRESAHA.116.307708 pubmed: 27081112 pmcid: 4939482
Wu, P., Liu, Z., Zhao, T., Xia, F., Gong, L., Zheng, Z., Chen, Z., Yang, T., & Duan, Q. (2019). Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling. Biochem. Biophys. Res. Commun., 512, 736–741. https://doi.org/10.1016/j.bbrc.2019.03.158
doi: 10.1016/j.bbrc.2019.03.158 pubmed: 30926167
Lin, M., Yuan, W., Su, Z., Lin, C., Huang, T., Chen, Y., & Wang, J. (2018). Yes-associated protein mediates angiotensin II-induced vascular smooth muscle cell phenotypic modulation and hypertensive vascular remodelling. Cell Prolif., 51, e12517. https://doi.org/10.1111/cpr.12517
doi: 10.1111/cpr.12517 pubmed: 30156340 pmcid: 6528929
Heger, J., Schiegnitz, E., von Waldthausen, D., Anwar, M. M., Piper, H. M., & Euler, G. (2010). Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J. Cell. Physiol., 224, 120–6. https://doi.org/10.1002/jcp.22102
doi: 10.1002/jcp.22102 pubmed: 20232299
Piek, A., de Boer, R. A., & Sillje, H. H. (2016). The fibrosis-cell death axis in heart failure. Heart Fail. Rev., 21, 199–211. https://doi.org/10.1007/s10741-016-9536-9
doi: 10.1007/s10741-016-9536-9 pubmed: 26883434 pmcid: 4762920

Auteurs

Jiawei Song (J)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Zhenzhou Zhang (Z)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Zhaojie Dong (Z)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Xinming Liu (X)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Ying Liu (Y)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Xueting Li (X)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Yingle Xu (Y)

Department of Psychiatry &, School of Medicine, Shanghai Institute of HypertensionRuijin HospitalShanghai Jiao Tong University, Shanghai, China.

Ying Guo (Y)

Department of Geratology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Ning Wang (N)

Department of Geratology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Miwen Zhang (M)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Yihang Chen (Y)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Haiyan Jin (H)

Department of Psychiatry &, School of Medicine, Shanghai Institute of HypertensionRuijin HospitalShanghai Jiao Tong University, Shanghai, China. hyjin603@163.com.

Jiuchang Zhong (J)

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. jczhong@sina.com.
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. jczhong@sina.com.
Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. jczhong@sina.com.
ORCID: 0000-0002-2315-3515

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis.

Alex Gough, Alice Sitch, Erica Ferris et al.
1.00
C-Reactive Protein Humans Biomarkers Inflammation

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Yanhui Yang, Ji Li, Yi Wang et al.
1.00
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Angiotensines › Angiotensine-II › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Exopeptidases › Carboxypeptidases › Angiotensin-converting enzyme 2 › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Eucaryotes › Animaux › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Apeline › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Cardiomyopathies › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines de la superfamille du TGF bêta › Facteurs de croissance et de différenciation › Facteur-15 de croissance et de différenciation › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Hypertension artérielle › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › MicroRNA-122-5p Aggravates Angiotensin...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › MicroRNA-122-5p Aggravates Angiotensin...